These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16120209)

  • 1. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
    BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
    J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
    Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
    Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival time of HIV-infected patients with cryptococcal meningitis.
    Chottanapund S; Singhasivanon P; Kaewkungwal J; Chamroonswasdi K; Manosuthi W
    J Med Assoc Thai; 2007 Oct; 90(10):2104-11. PubMed ID: 18041430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
    Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
    Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; ; ;
    Antivir Ther; 2009; 14(7):931-8. PubMed ID: 19918097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    João EC; Calvet GA; Menezes JA; D'Ippolito MM; Cruz ML; Salgado LA; Matos HJ
    Am J Obstet Gynecol; 2006 Jan; 194(1):199-202. PubMed ID: 16389032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.
    Bonnet F; Lawson-Ayayi S; Thiébaut R; Ramanampamonjy R; Lacoste D; Bernard N; Malvy D; Bonarek M; Djossou F; Beylot J; Dabis F; Morlat P;
    Clin Infect Dis; 2002 Nov; 35(10):1231-7. PubMed ID: 12410483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
    Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
    Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver enzymes elevation after HAART in HIV-HCV co-infection.
    Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
    J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
    Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
    Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting.
    Manosuthi W; Chaovavanich A; Tansuphaswadikul S; Prasithsirikul W; Inthong Y; Chottanapund S; Sittibusaya C; Moolasart V; Termvises P; Sungkanuparph S
    J Infect; 2007 Nov; 55(5):464-9. PubMed ID: 17714788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.